# [18F]FES PET/.CT in Uterine Cancer

> **NCT05916196** · PHASE2 · RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 30 (estimated)

## Conditions studied

- Uterine Cancer

## Interventions

- **DRUG:** 18F-Fluoroestradiol

## Key facts

- **NCT ID:** NCT05916196
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-05
- **Primary completion:** 2026-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05916196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05916196, "[18F]FES PET/.CT in Uterine Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05916196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*